Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06640972 · ClinicalTrials.gov registry record · Phase 2
Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists
A Phase 2 study of Triglycerides and Weight Gain Trajectory, sponsored by Response Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
- 1
- Study location
NCT06640972 is a Phase 2 study of Triglycerides and Weight Gain Trajectory that has completed, run by Response Pharmaceuticals. The registered enrollment target is 68 participants, roughly in line with the 69-participant average among 4 other Triglycerides trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT06640972, a Phase 2 study of Triglycerides and Weight Gain Trajectory, has completed, sponsored by Response Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn if drug RDX-002 works to treat high levels of fat (known as triglycerides, or TGs) in the blood in adults. It will also learn about the safety of drug RDX-002. The main question it aims to answer is if treatment with RDX-002 will lower triglycerides after a high-fat meal in patients who have recently stopped treatment with semaglutide or tirzepatide for obesity. The trial will also examine the effect of RDX-002 on body weight and fasting levels of cholesterol. Researchers will compare RDX-002 to a placebo (a look-alike substance that contains no drug) to see if RDX-002 works to reduce triglycerides. Participants will: Take drug RDX-002 or a placebo every day for 12 weeks Visit the clinic once every 4 weeks for checkups and tests
Conditions Studied
Interventions
- DRUG Placebo
- DRUG RDX-002
Study Locations (1)
Minnesota
- Nucleus Network - Saint Paul
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2024-09-27 |
| Est. Completion | 2025-05-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06640972
The ClinicalTrials.gov registry entry for NCT06640972 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 69-participant average among 4 other Triglycerides trials with a reported enrollment target. The listed sponsor is Response Pharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Triglycerides appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06640972 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT06640972 about?
NCT06640972 is a clinical study titled "Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists". The goal of this clinical trial is to learn if drug RDX-002 works to treat high levels of fat (known as triglycerides, or TGs) in the blood in adults. It will also learn about the safety of drug RDX-002. The main question it aims to answer is if treatment with RDX-002 will lower triglycerides after ...
What is the current status of trial NCT06640972?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2024-09-27. Estimated completion is 2025-05-13.
What conditions does trial NCT06640972 study?
This clinical trial studies the following conditions: Triglycerides, Weight Gain Trajectory, Cholesterol, Elevated.
What interventions are being tested in trial NCT06640972?
The interventions under investigation include: Placebo (DRUG), RDX-002 (DRUG).
Who is sponsoring clinical trial NCT06640972?
This trial is sponsored by Response Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06640972 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Triglycerides
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pilot Study of "Bottarga" Supplementation: A Little-known, Sustainable "Blue" Food
RECRUITING · NA
-
Curcumin & Astaxanthin for Lowering Triglyceride Readings and Inflammation
RECRUITING · NA
-
Effect of Diet on Vascular Disease in Pre-Menopausal Women
COMPLETED
-
Identifying Risk for Diabetes and Heart Disease in Women
COMPLETED
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.